Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 December 2022 | Story Lacea Loader | Photo Supplied
Prof Serges Kamga
Prof Serges Kamga, newly appointed Dean: Faculty of Law.

The Council of the University of the Free State (UFS) approved the appointment of Prof Serges Kamga as Dean of the Faculty of Law for a five-year term during its quarterly meeting on 25 November 2022. 

Prof Kamga is a full Professor of Law currently working at the Thabo Mbeki African School of Public and International Affairs (TMS) at the University of South Africa (UNISA).

“Prof Kamga’s excellent research reputation nationally and internationally, his extensive networks and partnerships will contribute to further raising the profile of the Faculty of Law nationally, on the continent and globally.  As an established NRF-rated researcher, he will also be able to enhance the research output of the faculty,” says Prof Francis Petersen, UFS Rector and Vice-Chancellor. 

“Prof Kamga will lead and manage the Faculty of Law in support of the UFS’ Vision 130 and the ultimate intent for the coming years to be a research-led, student-centred, and regionally engaged university that contributes to development and social justice through the production of globally competitive graduates and knowledge, and that impactfully supports societal development,” says Prof Petersen.  

Prof Kamga is co-director of the Cross-Cultural Human Rights Centre at the Free University of Amsterdam in the Netherlands. At times, he has acted as head of the Thabo Mbeki African Leadership Institute currently Thabo Mbeki School at UNISA and has had engagements at the United States Agency for International Development (USAID), the Young African Leaders Initiative, and as managing consultant at African Legal Sources at the University of Pretoria. In 2021, he received the prestigious Ali Mazrui Award for Scholarship and Research Excellence from the University of Texas at Austin in the USA.

He holds an LLD degree in Human Rights Law from the Centre for Human Rights, University of Pretoria. Prof Kamga has also worked as a researcher at the South African Institute for Advanced Constitutional, Public, Human Rights and International Law (SAIFAC). As a researcher, he has published in accredited journals and presented papers at various national and international conferences. 

“Prof Kamga’s experience in these positions, as well as his extensive knowledge and understanding of the South African and global law fraternity, places him in good standing to lead the faculty to become a formidable and impactful force nationally, on the continent, and abroad. He will also lead the faculty to exploit opportunities and deal with the challenges that the rapidly changing higher-education environment has to deal with,” says Prof Petersen.

Prof Kamga will assume duty on 1 February 2023.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept